All rights reserved. Subject to Notice of rights. ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Beta-blocker (95% CI) LOWb due to risk of bias (from 5 fewer to 60 fewer) All-cause mortality - CKD class 3-4 704 VERY LOWb,c due to risk of bias, imprecision (from 104 fewer to 7 more) Death or hospitalisation - CKD class 3a 669 VERY LOWb,c,e due to risk of bias, indirectness, imprecision Overalld (from 31 fewer to 165 fewer) Death or hospitalisation - CKD class 3b-4 235 VERY LOWb,c,e due to risk of bias, indirectness, imprecision Overalld (from 150 fewer to 18 more) Hospitalisation (time to event) - CKD class 3a 870 VERY LOWb,c due to risk of bias, imprecision (from 84 fewer to 31 more) Hospitalisation (time to event) - CKD class 3b-4 341 VERY LOWb,c due to risk of bias, imprecision (from 67 fewer to 248 fewer) Hospitalisation for cardiovascular disorder - CKD VERY LOWb,c,f due to risk of bias, (from 77 fewer to 56 more) Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 